Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 170569-86-5 Chemical Structure| 170569-86-5

Structure of SC-236
CAS No.: 170569-86-5

Chemical Structure| 170569-86-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SC-236 is an orally active inhibitor of COX-2. SC-236 displays anti-inflammatory properties and potent antimetastatic activity against both experimental metastases and spontaneous metastases arising following primary tumor excision.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SC-236

CAS No. :170569-86-5
Formula : C16H11ClF3N3O2S
M.W : 401.79
SMILES Code : O=S(C1=CC=C(N2N=C(C(F)(F)F)C=C2C3=CC=C(Cl)C=C3)C=C1)(N)=O
MDL No. :MFCD00941297
InChI Key :NSQNZEUFHPTJME-UHFFFAOYSA-N
Pubchem ID :9865808

Safety of SC-236

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301
Precautionary Statements:P301+P310
Class:6.1
UN#:2811
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
4T1 tumor cells 5 or 10 µM 24 hours To evaluate the effect of COX inhibition on tumor cell apoptosis and VEGF production. Results showed that both SC-236 and indomethacin significantly decreased VEGF production and increased tumor cell apoptosis. Br J Cancer. 2002 Jul 15;87(2):231-7
N/TERT-1 keratinocytes 5 µM 72 hours Test the inhibitory effect of SC-236 on COX-2 expression, results showed SC-236 significantly reduced COX-2 mRNA levels Front Immunol. 2017 Feb 10;8:82

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Carrageenan-induced paw inflammation model Subcutaneous injection 1 mg/kg and 12 mg/kg Single administration, observed for 24 hours To evaluate the effect of SC-236 on carrageenan-induced inflammatory responses. Results showed that low-dose SC-236 (1 mg/kg) reduced hyperalgesia, while high-dose (12 mg/kg) induced hypoalgesia, but had no significant effect on edema. Br J Pharmacol. 2002 Nov;137(6):837-44
Mice Partial hepatectomy model Gavage 10 mg/kg Twice daily until animal killing To evaluate the effect of SC-236 on liver regeneration, results showed that the COX-2-specific inhibitor significantly inhibited liver regeneration Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8885-90
Rat Carrageenan-induced knee joint inflammation model Intraperitoneal injection 16.8 mg/kg Single dose, observed for 4 hours To investigate the role of SC-236 in acute inflammatory response. Results showed that SC-236 significantly attenuated inflammatory hyperaemia, with no difference compared to indomethacin. J Physiol. 2002 Mar 1;539(Pt 2):579-87
Swiss Webster mice GAS myonecrosis model Intraperitoneal injection 2 mg/kg Every 12 hours for 72 hours To evaluate the effect of COX-2 selective NSAID on GAS myonecrosis, results showed that COX-2 selective NSAID did not significantly alter disease progression or antibiotic efficacy. J Infect Dis. 2014 May 1;209(9):1429-35
Male Wistar rats Acute arthritis model (C/K-induced) and chronic arthritis model (FCA-induced) Subcutaneous injection 2.8 mg/kg, 5.6 mg/kg, 11.2 mg/kg Prophylactic treatment: daily administration starting 1 hour before induction; Therapeutic treatment: daily administration starting from day 5 To evaluate the anti-inflammatory effects of SC-236 in acute and chronic arthritis models. Results showed that SC-236 dose-dependently inhibited joint swelling in the acute model and significantly reduced joint swelling and inflammatory markers (e.g., urinary PGE2 levels) in the chronic model. However, the anti-inflammatory effects of SC-236 were nullified when co-administered with L-NIL. Ann Rheum Dis. 2004 Dec;63(12):1564-70
Fischer 344 rats Intracerebral 9L gliosarcoma model Oral 3 mg/kg Once daily until death or euthanasia To compare the efficacy of SC-236 with dexamethasone in prolonging survival in a rat brain tumor model. Results showed that the median survival in the SC-236 group was 23 days, comparable to the dexamethasone group (23 days), both significantly better than the control group (16 days). Neuro Oncol. 2002 Jan;4(1):22-5
Rats Inflammatory hyperalgesia model L5-DRG injection 30, 70, 100, or 300 μg Single administration, evaluated after 30 minutes SC-236 significantly reduced mechanical hyperalgesia induced by IL-1β or carrageenan Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3603-8
Wistar rats CCK-octapeptide-induced acute pancreatitis Intravenous injection 4 mg/kg Three times daily for 5 days SC-236 ameliorated the severity of CCK-octapeptide-induced AP as measured by laboratory criteria [the pancreatic weight/body weight (p.w./b.w.) ratio, the level of serum amylase and lipase]. SC-236 also reduced pancreatic inflammatory changes such as edema, inflammation, vacuolization, and necrosis. World J Gastroenterol. 2007 Apr 28;13(16):2298-304
Rat Adjuvant-induced arthritis (AIA) model Intraperitoneal injection 5.6 mg/kg Daily for the first 3 days, then every second day for 10 days To investigate the effect of SC-236 on joint swelling and vascular dysfunction in a chronic arthritis model. Results showed that SC-236 significantly attenuated joint swelling but did not improve vascular dysfunction. J Physiol. 2004 Jun 1;557(Pt 2):635-43
BALB/c mice Orthotopic model of 4T1 mammary adenocarcinoma Intraperitoneal injection 6 mg/kg Daily for 13 days To assess the effect of SC-236 on primary tumor growth and metastasis. Results showed that SC-236 significantly reduced primary tumor size and the number of lung metastases, increased tumor cell apoptosis, and decreased microvessel density. Br J Cancer. 2002 Jul 15;87(2):231-7
BALB/c mice Mammary fat pad tumour model and experimental metastasis model Intraperitoneal injection 6 mg/kg Daily for 14 days SC-236 treatment significantly reduced tumour burden, the number and size of spontaneous metastases following primary tumour excision. SC-236 treatment also reduced tumour burden, the number and size of experimental metastases. Immunohistochemical staining demonstrated that COX-2 inhibition reduced microvessel density and increased apoptosis within both spontaneous and experimental metastases. Br J Cancer. 2004 Jul 19;91(2):359-65

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.49mL

0.50mL

0.25mL

12.44mL

2.49mL

1.24mL

24.89mL

4.98mL

2.49mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories